ABSTRACT The dose-response relationships of the anticholinergic bronchodilator drug ipratropium bromide were studied. Cumulative doses totalling 288 
The inhalation of low doses of a bronchodilator drug from a pressurised metered-dose inhaler is standard practice in the maintenance treatment of reversible airflow obstruction. For acute exacerbations necessitating admission to hospital large doses of the bronchodilator are often administered by nebulisation of a solution of the drug, with or without the assistance of intermittent positive-pressure ventilation. Previous reports [1] [2] [3] of the superiority of liquid nebulisation over a metered-dose inhaler for administering f3-adrenoceptor bronchodilator aerosols appear to overlook the discrepancy between the doses administered. We have made a comparative study of the bronchodilator effect of the anticholinergic drug ipratropium bromide given in equal, low doses by jet nebulisation and from a metered-dose inhaler. Ipratropium bromide is being used increasingly in the treatment of patients with airflow obstruction, a dose of 20-80 ,g from a metered-dose inhaler producing a peak effect after 30-40 minutes and an action which may persist for up to six hours. 4 6 The objectives of the present study were twofold: firstly, to determine the dose of ipratropium given as a nebulised solution which was needed to produce a plateau in the magnitude of the resulting bronchodilatation and, secondly, to compare the dose-response relationships of administering equal doses of the drug from a Wright nebuliser and a metered-dose inhaler.
Methods
The study was performed on 10 patients aged 20-67 years, whose clinical details are summarised in table 1. Eight of the subjects had bronchial asthma and two chronic bronchitis; nine were non-smokers. Individuals were excluded if they had evidence of any other bronchopulmonary disease or disease in any other system. Each patient gave informed con-297 
DOSE-RESPONSE COMPARISON USING METERED-DOSE INHALER AND JE T NEBULISATION
The patients attended the laboratory on two consecutive days. They rested for 20 minutes and control values of peak expiratory flow rate, FEV, forced vital capacity (FVC), thoracic gas volume (TGV), airways resistance (Raw), and pulse rate were recorded. Measurements of PEFR, FEV,, and FVC were made with an Ohio 842 spirometer. A pressure-corrected flow plethysmograph (Fenyves and Gut) was used to measure TGV and Raw"I and the results were expressed as the reciprocal of airways resistance per litre of thoracic gas volumethat is, specific airways conductance (sGaw).
On one treatment day each subject received ipratropium bromide from a metered-dose inhaler at 30-minute intervals in doses of 18, 18, and 36 ,ug. On the other treatment day ipratropium was inhaled through a face mask from the Wright nebuliser in doses of 9, 9, 18, and 36 ,ug at 30-minute intervals. FVC-forced vital capacity; PERF-peak expiratory flow rate; sGaw-specific conductance; TGV-thoracic gas volume.
*The mean improvement in FEV, FVC, PEFR, TGV, and sGaw compared to baseline values was significant (p < 0-001) at the cumulated 18, 36, and 72 ug dose levels anA at 30 and 60 minutes. Improvement in FVC, TGV, and sGaw was not significant at the 9,g dose (n = 10). 
Discussion
The results of the initial study in this group of patients with moderately severe airflow obstruction showed that about 80% of the maximum bronchodilatation produced by ipratropium bromide could be achieved with a cumulative dose of 72 ftg.
When the effects of equivalent doses of the drug given by metered-dose inhaler and as a nebulised solution were then compared there was no evident difference in the degree of bronchodilatation achieved.
Important factors influencing aerosol penetration into the lungs include the size and distribution of the particles inhaled,'4 the technique of inhalation,'5-7 and abnormalities in the airway structure.'8 The diameter of particles delivered by a metered-dose inhaler is reported to be below 5 ,tm'9 and from a Wright nebuliser below 8 ,m.'0 In the present study the techniques of inhalation of the bronchodilator under investigation were intentionally different but the degree of airflow obstruction in the participants was of comparable severity on the days when ipratropium was administered by the two methods.
Shenfield and coworkers20 reported that less than 20% of the delivered dose of nebulised salbutamol enters the patient, the proportion reaching the lungs being uncertain; while 10% of the delivered dose from a metered-dose inhaler is estimated to enter the lungs.21 22 Another potential difficulty in paramyotonia congenita relates to the electrolyte shifts which may occur with haemodilution and cardiopulmonary bypass. In particular, hyperkalaemia may precipitate myotonia.' The primary muscle defect is thought to be related to increased sodium conductance in affected muscles. An infusion of 80 mmol (mEq) of potassium chloride in 500 ml 5% dextrose infused at 80 ml/h was able to prevent gross fluctuations in serum potassium concentrations in this patient.
Only minimal postoperative respiratory depression was seen, with a transient rise in arterial Pco2. The major postoperative difficulty encountered was the occurrence of brief episodes of hypotension and falling central venous pressures, which were not significantly affected by volume loading or by dopamine infusion. Although the aetiology of these haemodynamic changes is not definitely known, they were possibly related to sudden changes in peripheral resistance or venous capacitance or both. The attacks proved benign, though they did increase the duration of the patient's stay in the intensive care unit.
In summary, cardiopulmonary bypass using moderate hypothermia has been undertaken safely in a patient with paramyotonia congenita. Depolarising muscle relaxants and halothane were avoided, and complete rewarming on bypass was carefully carried out. The anticipated respiratory difficulties did not occur and postoperative recovery was complete.
